Fassnacht, Martin

Radiotherapy in adrenocortical carcinoma

Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer

Adrenal and Paraganglionic TumorsPituitary Gland Disorders and Treatments

Cited by 189

Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites

Eisenhofer, G., Prejbisz, A., Peitzsch, M., Pamporaki, C., Masjkur, J., Rogowski-Lehmann, N., Langton, K., Tsourdi, E., Pęczkowska, M., Fliedner, S., et al. (2018) · Clinical Chemistry

Adrenal and Paraganglionic TumorsMetabolism and Genetic Disorders

Cited by 181

Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma

Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 176

Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial

Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 175

Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study

Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 173

Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree

Lesch, K.-P., Selch, S., Renner, T. J., Jacob, C., Nguyen, T. T., Hahn, T., Romanos, M., Walitza, S., Shoichet, S., Dempfle, A., et al. (2011) · Molecular Psychiatry

Genomic variations and chromosomal abnormalitiesAttention Deficit Hyperactivity Disorder

Cited by 167

Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5α-Reductase Activity in Women with Polycystic Ovary Syndrome

Fassnacht, M., Schlenz, N., Schneider, S. B., Wudy, S. A., Allolio, B., & Arlt, W. (2003) · The Journal of Clinical Endocrinology & Metabolism

Ovarian function and disordersAdrenal Hormones and Disorders

Cited by 158

The role of surgery in the management of recurrent adrenocortical carcinoma

Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 154

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement

Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 154

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma: CYP3A4 induction by mitotane

Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology

Pharmacogenetics and Drug MetabolismAdrenal and Paraganglionic Tumors

Cited by 148

β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma

Gaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 146

Diagnosis of endocrine disease: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis

Bancos, I., Tamhane, S., Shah, M., Delivanis, D. A., Alahdab, F., Arlt, W., Fassnacht, M., & Murad, M. H. (2016) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 144

Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature

Di Dalmazi, G., Berr, C. M., Fassnacht, M., Beuschlein, F., & Reincke, M. (2014) · The Journal of Clinical Endocrinology & Metabolism

Adrenal Hormones and DisordersPituitary Gland Disorders and Treatments

Cited by 139

Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection

Terzolo, M., Baudin, A. E., Ardito, A., Kroiss, M., Leboulleux, S., Daffara, F., Perotti, P., Feelders, R. A., deVries, J. H., Zaggia, B., et al. (2013) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 134

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 133

Adrenal incidentalomas: a manifestation of the metabolic syndrome?

Reincke, M., Faßnacht, M., Väth, S., Mora, P., & Allolio, B. (1996) · Endocrine Research

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 133

CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma

Canu, L., Van Hemert, J. A. W., Kerstens, M. N., Hartman, R. P., Khanna, A., Kraljevic, I., Kastelan, D., Badiu, C., Ambroziak, U., Tabarin, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research Advances

Cited by 131

Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis

Pelsma, I. C. M., Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 130

Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing’s syndrome: a European multicentric study

Di Dalmazi, G., Kisker, C., Calebiro, D., Mannelli, M., Canu, L., Arnaldi, G., Quinkler, M., Rayes, N., Tabarin, A., Laure Jullié, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsPituitary Gland Disorders and Treatments

Cited by 119

TP53 Germline Mutations in Adult Patients with Adrenocortical Carcinoma

Herrmann, L. J. M., Heinze, B., Fassnacht, M., Willenberg, H. S., Quinkler, M., Reisch, N., Zink, M., Allolio, B., & Hahner, S. (2012) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsGenetic factors in colorectal cancer

Cited by 109

[123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes

Hahner, S., Stuermer, A., Kreissl, M., Reiners, C., Fassnacht, M., Haenscheid, H., Beuschlein, F., Zink, M., Lang, K., Allolio, B., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 95

Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation

Ronchi, C. L., Di Dalmazi, G., Faillot, S., Sbiera, S., Assié, G., Weigand, I., Calebiro, D., Schwarzmayr, T., Appenzeller, S., Rubin, B., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 93

Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma

Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 93

Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis

Vanbrabant, T., Fassnacht, M., Assie, G., & Dekkers, O. M. (2018) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 91